奎诺林和库马林异醇衍生物:合成,抗瘤评估和分子对接研究与Bcl-2
Martina Piškor1, Marina Ter1, Leentje Persoons2
1Department of Organic Chemistry, Faculty of Chemical Engineering and Technology, University of Zagreb Marulićev trg 19 10000 Zagreb Croatia sraic@fkit.unizg.hr.
RSC advances
|December 19, 2025
概括
一种新型的氨酸胺胺,化合物8f,通过向Bcl-2显示强大和选择性的抗癌活性,对抗血液和胰腺癌. 这一发现为难以治疗的恶性瘤提供了一个有希望的新疗法策略.
科学领域:
- 药用化学 医学化学
- 癌症生物学 癌症生物学
- 化学生物学 化学生物学
背景情况:
- 胰腺和血液恶性瘤的传统疗法经常面临抗药性,需要开发新的抗癌药物.
- 选择性诱导瘤细胞死亡是有效治疗癌症的关键目标.
研究的目的:
- 设计,合成和评估新型素和氨酸衍生异醇类似物及其金属复合物作为潜在的抗癌剂.
- 识别具有强大的抗增殖活性和对癌细胞有选择性的化合物.
主要方法:
- 合成基诺林和氨酸衍生异醇类似物及其Re (i) /Ru (ii) 复合物.
- 针对人类癌细胞系和外周血液单核细胞 (PBMCs) 的抗增殖试验.
- 分子对接研究预测与Bcl-2的结合相互作用.
主要成果:
- 昆氨基胺8f显示出强大的抗增殖活性 (IC50:2.1-4.7μM) 对抗血液癌和胰腺腺癌.
- 化合物8f对癌细胞的选择性高于PBMC (选择性指数高达48).
- 分子对接显示了8f与Bcl-2的稳定和有利的结合 (ΔG_bind = -84.98 kcal mol-1).
结论:
- 化合物8f是开发新型选择性Bcl-2-向抗癌疗法的有前途的化合物.
- 这项研究强调了氨酸胺基胺衍生物在瘤学药物发现中的潜力.
更多相关视频
09:20Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts
Published on: June 26, 2018
8.7K
07:40A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
Published on: May 27, 2021
4.5K
相关概念视频
Combination Therapies and Personalized Medicine
5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
